Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Canakinumab vs Potassium: Potassium has the stronger overall evidence (8.5 vs 4/10); they're alternatives for reduce inflammation — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Potassium wins 3 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Probably helps
9 of 14 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (2)
Outcomes where both Canakinumab and Potassium have evidence — compare verdict strength side-by-side.
A prescription biologic, not self-administered for longevity. Approved CAPS dosing is 150 mg subcutaneously every 8 weeks (weight-adjusted in children). The CANTOS cardiovascular regimen was 150 mg subcutaneously every 3 months. There is NO established off-label longevity protocol, and cost is prohibitive.
any
Subcutaneous injection (clinician-administered)
99-500mg daily from supplements (food provides more)
With food to reduce GI upset, Spread throughout day, During/after exercise for athletes
Potassium Citrate or Potassium Gluconate
Months to years
Weeks
Trial endpoints
Throughout use
2-4 weeks
1-2 weeks
Long-term
With excess or kidney issues
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
The New England journal of medicine (2017) · Rct · n=10061
CANTOS: randomized, double-blind, placebo-controlled trial in ~10,000 post-MI patients with elevated hsCRP
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
Lancet (2017) · Rct
Exploratory analysis of the CANTOS cohort — incident and fatal lung cancer as pre-specified secondary endpoints
Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial.
Lung cancer (Amsterdam, Netherlands) (2024) · Rct · n=237
CANOPY-2: phase 3 randomized, double-blind trial in advanced non-small-cell lung cancer
Effect of changes in potassium intake on blood pressure: a dose–response meta-analysis of randomized clinical trials (2000–2024)
Clinical Kidney Journal (2025) · Meta analysis · n=2500
Dose-response analysis of RCTs from 2000-2024
Magnesium and Potassium Supplementation for Systolic Blood Pressure Reduction in the General Normotensive Population: A Systematic Review and Subgroup Meta-Analysis for Optimal Dosage and Treatment Length
Nutrients (2024) · Meta analysis
Both supplements demonstrated greater reductions in SBP for the general population at lower dosages and longer treatment durations.
Sex-specific associations between sodium and potassium intake and overall and cause-specific mortality: a large prospective U.S. cohort study, systematic review, and updated meta-analysis of cohort studies
BMC medicine (2024) · Meta analysis · n=237036
Meta-analysis examining Potassium efficacy
Potassium has a higher evidence score (8.5/10 vs 4/10) and wins in 3 of 3 categories.
For reduce inflammation, Potassium has a higher relevance score (85 vs 62).
No known interactions between Canakinumab and Potassium have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.